Unfractionated heparin inhibits thrombin-catalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa
- 1 January 1989
- journal article
- research article
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 257 (1) , 143-150
- https://doi.org/10.1042/bj2570143
Abstract
We have proposed previously that the steps in coagulation most sensitive to inhibition by heparin are the thrombin-dependent amplification reactions, and that prothrombinase is formed in heparinized plasma only after Factor Xa activates Factor VIII and Factor V. These propositions were based on the demonstration that both heparin and Phe-Pro-Arg-CH2Cl completely inhibited 125I-prothrombin activation for up to 60 s when contact-activated plasma (CAP) was replenished with Ca2+. Furthermore, the addition of thrombin to CAP before heparin or Phe-Pro-Arg-CH2Cl completely reversed their inhibitory effects. Additional support for the above hypotheses is provided in this study by demonstrating that, when the activity of thrombin is suppressed by heparin (indirectly) or by Phe-Pro-Arg-CH2Cl (directly), exogenous Factor Xa reverses the ability of these two agents to inhibit prothrombin activation. Prothrombin activation was initiated by adding Factor Xa (1 nM) or thrombin (1 or 10 nM) simultaneously with CaCl2 to CAP. In the absence of heparin or Phe-Pro-Arg-CH2Cl, prothrombin activation was seen 15 s later in either case. Heparin failed to delay, and Phe-Pro-Arg-CH2Cl delayed for 15 s, prothrombin activation in CAP supplemented with Factor Xa. In contrast, heparin and Phe-Pro-Arg-CH2Cl completely inhibited prothrombin activation for at least 45 s in CAP supplemented with 1 nM-thrombin. Heparin failed to delay prothrombin activation in CAP supplemented with 10 nM-thrombin, whereas Phe-Pro-Arg-CH2Cl completely inhibited prothrombin activation in this plasma for 45 s. These results suggest that in CAP: (1) Factor Xa can effectively activate Factor VIII and Factor V when the proteolytic activity of thrombin is suppressed; (2) heparin-antithrombin III is less able to inhibit Factor Xa than thrombin; (3) suppression of the thrombin-dependent amplification reactions is the primary anticoagulant effect of heparin.This publication has 21 references indexed in Scilit:
- Increased sulphation improves the anticoagulant activities of heparan sulphate and dermatan sulphateBiochemical Journal, 1987
- The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparinBiochemical Journal, 1987
- The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulphateBritish Journal of Haematology, 1985
- Purification and biological property of heparin cofactor II: Activation of heparin cofactor II and antithrombin III by dextran sulfate and various glycosaminoglycansThrombosis Research, 1984
- The isolation of prothrombin, factor IX and factor X from human factor IX concentratesThrombosis Research, 1984
- Activation of factor X and prothrombin in antithrombin-III depleted plasma: The effects of heparinThrombosis Research, 1981
- Preparation and partial characterization of human plasma depleted of antithrombin-III by heparin-sepharose affinity chromatographyThrombosis Research, 1980
- Preparation and properties of bovine factor VIII (antihemophilic factor)Biochemistry, 1980
- D-PHE-PRO-ARGCH2Cl-A selective affinity label for thrombinThrombosis Research, 1979
- The activation of factor V by factor Xa or α-chymotrypsin and comparison with thrombin and RVV-V action. An improved factor V isolation procedureBiochemistry, 1976